Peptide-coupled Red Blood Cells for the Treatment of Multiple Sclerosis
Status:
ACTIVE_NOT_RECRUITING
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
RED4MS is a clinical trial to assess the safety and tolerability of autologous peptide coupled red blood cells (CLS12311) in patients with relapsing remitting multiple sclerosis (RRMS). CLS12311 consists of autologous red blood cells (RBCs) coupled with antigenic peptides and aims to treat RRMS by induction of antigen-specific immune tolerance.
Phase:
PHASE1
Details
Lead Sponsor:
Cellerys AG
Collaborators:
Jung Diagnostics GmbH Novartis Scope International AG Tetec AG